Drug Type Small molecule drug |
Synonyms BDDE cross-linked hyaluronic acid, Butanediol diglycidyl ether cross-linked hyaluronic acid, Cross-linked hyaluronic acid + [9] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (15 Oct 2013), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoarthritis, Knee | CN | 28 Mar 2023 | |
Osteoarthritis | KR | 15 Oct 2013 |
Not Applicable | 1,949 | axzdfkyrhe(ezsnixypmi) = The incidence of adverse drug reactions other than injection-site reactions was 0.67%. Most adverse events were of mild severity. No serious adverse events related to the study drug were reported. qngkuxwvna (ipkajoqora ) View more | Positive | 15 Jul 2021 | |||
Not Applicable | - | 55 | ojutmxnlxt(hybqhxwaex) = xyjrdlvrun dkhgqzmghz (qcnqjnhzgi ) | - | 01 Mar 2012 |